| Mar'19 | Mar'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||
Net loss | ||||||
-6,558 | -10,715 | -18,044 | -3,720 | -3,482 | ||
Adjustments to reconcile net loss to net cash used in operating activities | ||||||
Depreciation and amortization of property and equipment | ||||||
64 | - | 38 | - | - | ||
Depreciation | ||||||
- | - | - | 25 | 26 | ||
Capital loss in respect to property and equipment | ||||||
- | - | - | -5 | 0 | ||
Stock-based compensation | ||||||
2,399 | 574 | 4,384 | 365 | 447 | ||
Unrealized loss on marketable securities to available for sale marketable securities | ||||||
3,498 | - | - | - | - | ||
Change in fair value of warrant liabilities | ||||||
- | - | - | 0 | - | ||
Revaluation of warrants to purchase Common Stock | ||||||
- | - | - | 0 | -152 | ||
Imputed interest on Convertible Notes, loans from related parties and others | ||||||
- | - | - | 299 | 217 | ||
Waiver of salary by the Company's officer | ||||||
- | - | - | 304 | 0 | ||
Change in fair value of warrant liabilities | ||||||
- | -793 | -5,412 | - | - | ||
Change of management's assessment of prior year research and development to licensing right to use technology | ||||||
200 | - | - | - | - | ||
Adjustment due to adoption of ASU 2016-01 (Note 2) | ||||||
-2 | -2 | - | - | - | ||
Amortization of beneficial conversion feature and debt discount related to convertible notes upon merger | ||||||
- | - | 1,045 | - | - | ||
Issuance of Common Stock to finder upon the conversion of Convertible Notes | ||||||
- | - | - | 0 | - | ||
Amortization of beneficial conversion feature and debt issuance costs related to Convertible Notes | ||||||
- | - | - | 1,050 | 768 | ||
Issuance cost related to warrants to investors and placement agent | ||||||
- | - | -457 | 0 | - | ||
Imputed interest on convertible notes and others | ||||||
- | - | -33 | - | - | ||
Issuance of common stock to finder upon the conversion of convertible notes | ||||||
- | - | 18 | - | - | ||
Changes in: | ||||||
Other current assets and prepaid expenses | ||||||
729 | -117 | 31 | - | - | ||
Other accounts receivables and prepaid expenses | ||||||
- | - | - | 67 | -38 | ||
Accounts payable | ||||||
322 | 293 | 141 | 404 | 10 | ||
Accrued expenses | ||||||
276 | 196 | -573 | - | - | ||
Deferred revenue | ||||||
2,263 | - | - | - | - | ||
Other accounts payable | ||||||
- | - | - | 291 | 166 | ||
Deferred IPO costs that was aborted | ||||||
- | - | - | 352 | 0 | ||
Net cash used in operating activities | ||||||
1,341 | -8,692 | -7,118 | -692 | - | ||
Net cash used in operating activities | ||||||
- | - | - | - | -1,658 | ||
Cash flows from investing activities | ||||||
Investment in marketable securities | ||||||
12,222 | 8,304 | 2,000 | 0 | - | ||
Proceeds from redemption of marketable securities | ||||||
10,485 | - | 1,396 | 0 | - | ||
Purchase price paid for the merger | ||||||
- | - | 294 | 0 | - | ||
Maturity of restricted bank deposits | ||||||
- | - | - | - | 0 | ||
Selling of property and equipment | ||||||
- | - | - | 12 | 0 | ||
Purchase of property and equipment | ||||||
56 | 219 | 244 | -2 | 7 | ||
Net cash (used in) provided by investing activities | ||||||
-1,793 | -8,523 | -1,143 | 14 | - | ||
Net cash used in investing activities | ||||||
- | - | - | - | -7 | ||
Cash flows from financing activities | ||||||
Proceeds from the issuance of units consisting of common stock and warrants, net of offering cost | ||||||
- | - | 9,888 | 0 | - | ||
Proceeds from issuance of units consist of Common Stock and warrants, net of issuance costs | ||||||
- | - | - | - | 540 | ||
Purchase of treasury stock | ||||||
- | - | 25 | 0 | - | ||
Maturity of loan and interest from related parties and others | ||||||
- | - | 418 | 0 | - | ||
Proceeds from issuance of convertible notes, net of issuance cost | ||||||
- | 10,813 | - | - | - | ||
Issuance of common stock related to at the market offerings, net of offering costs | ||||||
799 | - | - | - | - | ||
Proceeds from loan | ||||||
292 | - | - | - | - | ||
Payment of loan | ||||||
28 | - | 41 | - | - | ||
Proceeds from loan from related parties and others | ||||||
- | - | 56 | 340 | 0 | ||
Proceeds from issuance of Convertible Note | ||||||
- | - | - | 184 | 1,239 | ||
Deferred IPO costs that were paid | ||||||
- | - | - | - | 146 | ||
Deferred private placement costs that were paid | ||||||
- | - | - | 4 | 0 | ||
Proceeds from the exercise of stock options | ||||||
8 | - | 1 | 0 | - | ||
Proceeds from bank loan | ||||||
- | - | - | 467 | 0 | ||
Payment of line of credit | ||||||
- | - | - | 431 | 0 | ||
Net cash provided by financing activities | ||||||
1,071 | 10,813 | 9,461 | 556 | - | ||
Increase (decrease) in cash, cash equivalents and restricted cash | ||||||
618 | -6,402 | 1,200 | -122 | - | ||
Supplemental disclosure of cash flow items: | ||||||
Conversion of convertible notes to common stock | ||||||
- | - | 3,955 | - | - | ||
Fair market value of options issued to NitricGen for the licensing right to use technology | ||||||
295 | - | - | - | - | ||
Fair market value of stock to be issued to vendor | ||||||
144 | - | - | - | - | ||
Net cash (used in) provided by financing activities | ||||||
- | - | - | - | 1,633 | ||
Increase (decrease) in cash and cash equivalents | ||||||
- | - | - | - | -32 | ||
Conversion of Convertible Notes into Common Stock | ||||||
- | - | - | 0 | 2,873 | ||
Capitalization of deferred private placement costs | ||||||
- | - | - | 86 | - | ||
Issuance costs related to warrants | ||||||
- | - | - | 0 | - | ||
Capitalization of deferred private placement costs | ||||||
- | - | - | - | 0 | ||